Sequential continual reassessment method for two-dimensional dose finding

Statistics in Medicine

Volumn 27, Issue 27, 2008, Pages 5664-5678

  Yuan, Ying ^a   Yin, Guosheng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adaptive design; Drug combination; Phase I trial

Indexed keywords

DRUG;

ARTICLE; COMPARATIVE STUDY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG TOXICITY; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; SAMPLE SIZE; STATISTICAL MODEL;

CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 58749104211     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3372     Document Type: Article

References (31)

1. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45:925-937.
2. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46:33-48.
3. Korn E, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon R. A comparison of two phase I trial designs. Statistics in Medicine 1994; 13:1799-1806.
4. Møller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 1995; 14:911-922.
5. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14:1149-1161.
6. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.
7. Mukhopadhyay S. Bayesian nonparametric inference on the dose level with specified response rate. Biometrics 2000; 56:220-226.
8. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998; 17:1103-1120.
9. Gasparini M, Eisele J. A curve-free method for phase I clinical trials. Biometrics 2000; 56:609-615.
10. Whitehead J, Brunier H. Bayesian decision procedures for dose determining experiments. Statistics in Medicine 1995; 14:885-893.
11. Leung DHY, Wang YG. An extension of the continual reassessment method using decision theory. Statistics in Medicine 2002; 21:51-63.
12. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for phase I clinical trials. Biometrics 1997; 53:745-760.
13. Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002; 58:171-177.
14. Yuan Z, Chappell R, Bailey H. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics 2007; 63:173-179.
15. O'Quigley J. Curve-free and model-based continual reassessment method designs. Biometrics 2002; 58:245-249.
16. Elder L. Overview of phase I trials. In Statistics in Clinical Oncology, Crowley J (ed.). Marcel Dekker: New York, 2001; 1-34.
17. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Statistics in Medicine 2002; 21:2757-2770.
18. Braun TM, Thall PF, Nguyen H, Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clinical Trials 2007; 4:113-124.
19. Mayer K, Karim S, Kelly C, Maslankowski L, Rees H, Profy A, Day J, Welch J, Rosenberg Z. Safety and tolerability of vaginal pro 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003; 17:321-329.
20. Kramar A, Lebecq A, Candalh E. Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Statistics in Medicine 1999; 18:1849-1864.
21. Kuzuya K, Ishikawa H, Nakanishi T, Kikkawa F, Nawa A, Fujimura H, Iwase A, Arii Y, Kawai M, Hattori S, Sakakibara K, Sasayama E, Furuhashi Y, Suzuki T, Mizutani S. Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study. International Journal of Clinical Oncology 2001; 6:271-278.
22. Ashford J. General models for the joint action of mixtures of drugs. Biometrics 1981; 37:457-474.
23. Abdelbasit KM, Plackett RL. Experimental design for joint action. Biometrics 1982; 38:171-179.
24. Simon R, Korn E. Selecting drug combinations based on total equivalent dose (dose intensity). Journal of the National Cancer Institute 1990; 82:1469-1476.
25. Korn E, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. Journal of Clinical Oncology 1993; 11:794-801.
26. Thall PF, Millikan RE, Müller P, Lee SJ. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59:487-496.
27. Conaway MR, Dunbar S, Peddada SD. Designs for single- or multiple-agent phase I trials. Biometrics 2004; 60:661-669.
28. Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics 2005; 61:217-222.
29. Yin G, Yuan Y. A latent contingency table approach to dose-finding for combinations of two agents. Biometrics 2008; to appear.
30. Piantadosi S, Liu G. Improved designs for phase I studies using pharmacokinetic measurements. Statistics in Medicine 1996; 15:1605-1618.
31. Gajewski BJ, Simon SD, Carlson SE. Predicting accrual in clinical trials with Bayesian posterior predictive distributions. Statistics in Medicine 2008; 27:2328-2340.